Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjFRA:5NX +6.07%69 10-Year ROIIC % is 131.36 as of Dec. 2025. GuruFocus rates FRA:5NX with a GF Score™ of 69/100 and a GF Value™ of €9.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Nexstim Oyj ranks better than 95.07% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Nexstim Oyj's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 131.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Nexstim Oyj's 10-Year ROIIC % or its related term are showing as below:
FRA:5NX's 10-Year ROIIC % is ranked better than 95.07% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 2.3
vs FRA:5NX: 131.36
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Nexstim Oyj 10-Year ROIIC % Related Terms
Nexstim Oyj 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5NX vs ABT, SYK, MDT: 10-Year ROIIC % Comparison
For the Medical Devices subindustry, Nexstim Oyj's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's 10-Year ROIIC % falls into.
Nexstim Oyj's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 0.6316116 (Dec. 2025) - -10.37 (Dec. 2015) )
/
( 10.681 (Dec. 2025) - 2.306 (Dec. 2015) )
=
11.0016116
/
8.375
=
131.36%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Nexstim Oyj (FRA:5NX) has a 10-Year ROIIC % of 131.36 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Nexstim Oyj and its competitors. According to the industry distribution chart, Nexstim Oyj ranks #34 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 4.9%.
Is Nexstim Oyj's 10-Year ROIIC % too high?
Nexstim Oyj's current 10-Year ROIIC % is 131.36. The Medical Devices & Instruments industry median 10-Year ROIIC % is 2.30. Nexstim Oyj's value of 131.36 is 5611.3% above this industry median. Based on the distribution chart, Nexstim Oyj ranks #34 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nexstim Oyj has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's 10-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #34 out of 690 companies for 10-Year ROIIC %. This places Nexstim Oyj in the top 5% of its industry — outperforming the majority of peers. The industry median 10-Year ROIIC % is 2.30. Nexstim Oyj's value of 131.36 is 5611.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.30, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexstim Oyj's current 10-Year ROIIC % of 131.36 is 5611.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Nexstim Oyj and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current 10-Year ROIIC % is 131.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (FRA:5NX) is currently considered Fairly Valued. The stock's GF Value™ is €9.65, compared to a current price of €9.78 — trading 1.3% above its estimated fair value. The current 10-Year ROIIC % is 131.36 and 5611.3% above the Medical Devices & Instruments industry median of 2.30. Nexstim Oyj's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Nexstim Oyj (FRA:5NX), the current 10-Year ROIIC % is 131.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65.
GuruFocus considers Nexstim Oyj to be Fairly Valued.
Key valuation signals for FRA:5NX:
10-Year ROIIC %: 131.36
GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
Industry Position: 5611.3% above the Medical Devices & Instruments median (#34 of 690)
No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score
Get the complete analysis for FRA:5NX
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5NX has been successfully added to your 
